Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting

SAN DIEGO, Sept 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (NASDAQ: OREX) , a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced its active calendar of events for October 2008, which includes six data presentations and one sponsored symposium at The Obesity Society Annual Scientific Meeting, as well as upcoming corporate presentations at noteworthy investor conferences.

    The Obesity Society Annual Scientific Meeting, Phoenix Convention Center

    Saturday, October 4
    Poster Presentation
    Abstract: 317-P
    Title: "The Naltrexone-Bupropion Combination Reduces the Prevalence of the
    Metabolic Syndrome and Improves Cardiometabolic Markers in At-Risk
    Subjects"
    Time:  5:00-7:00 p.m. MT

    Sunday, October 5
    Symposium
    Event Code: E1280
    Title: "Reward and Obesity; Too Much of a Good Thing?"
    Time: 6:15-7:45 a.m. MT
    Location: Hyatt Regency Phoenix, Regency Ballroom A/B

    Oral Presentation
    Abstract: 61-OR
    Presenter:  Ronald Landbloom, M.D.
    Title: "Long Term Weight Loss from a Dose Optimization Study with
    Zonisamide SR and Bupropion SR"
    Time: 11:00-11:15 a.m. MT

    Poster Presentation
    Abstract: 585-P
    Title: "Relative Bioavailability of Sustained-release (SR) versus
    Immediate-release (IR) Naltrexone (NAL) Formulations in Healthy Obese
    Volunteers: Implications for Improved Tolerability?"
    Time: 5:30-7:30 p.m. MT

    Monday, October 6
    Oral Presentation
    Abstract: 104-OR
    Presenter: Sonja K. Billes, Ph.D.
    Title: "Leptin Regulates Food Intake Via Dopamine Receptor-Dependent
    Mechanisms"
    Time: 11:30-11:45 a.m. MT

    Poster Presentation
    Abstract: 847-P
    Title: "Quality of Life Improvements from a Dose Optimization Study with
    Zonisamide SR and Bupropion SR"
    Time: 12:45-2:45 p.m. MT

    Poster Presentation
    Abstract: 848-P
    Title: "Timing of Response from a Dose Optimization Study with Zonisamide
    SR and Bupropion SR"
    Time: 12:45-2:45 p.m. MT

    Upcoming Corporate Presentations
    JMP Securities Healthcare Sector Focus Conference
    Le Parker Meridien, New York
    October 6, 2008
    10:00 a.m. ET

    BIOCOM Investor Conference
    Hyatt Regency La Jolla, San Diego
    October 28, 2008
    4:00 p.m. PT

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in late-stage of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.